

Supplementary Table S1. Comparative analysis of average survival time after surgery in CC patients with GPR55(-) and GPR55(+) without prognostic value

Patient Group	Category	5 Years Follow-Up after Surgery			12 Years Follow-Up after Surgery		
		Disease-free Survival ^a			Disease-free Survival ^a		
		Average (Months)	Difference (Months)	<i>P</i> -value	Average (Months)	Difference (Months)	<i>P</i> -value
CEA ^c	GPR55 (-) ^b	35	7	0.586	56	8	0.779
	GPR55(+)	42			64		
CXCL16 ^d	GPR55 (-)	56	2	0.751	112	3	0.621
	GPR55(+)	54			109		
CXCL17 ^e	GPR55 (-)	55	1	0.949	109	7	0.169
	GPR55(+)	56			116		
GPR35 V2/3 ^f	GPR55 (-)	52	2	0.649	101	9	0.167
	GPR55(+)	54			110		
LGR5 ^g	GPR55 (-)	56	1	0.855	109	3	0.328
	GPR55(+)	55			112		

(a) Mean survival time after surgery calculated by cumulative survival analysis according to Kaplan-Meier model

(b) CC patients divided into two groups, GPR55(-) and GPR55(+) using a cutoff of 0.1365 mRNA copies/ 18S rRNA unit

(c) CC patient group with CEA mRNA levels above 3.67 mRNA copies/18S rRNA unit

(d) CC patient group with CXCL16 mRNA levels below 7.2 mRNA copies/18S rRNA unit

(e) CC patient group with CXCL17 mRNA levels above 0.0003 mRNA copies/18S rRNA unit

(f) CC patient group with GPR35 V2/3 mRNA levels below 11.7 mRNA copies/18S rRNA unit

(g) CC patient group with LGR5 mRNA levels below 0.062 mRNA copies/18S rRNA unit